Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ENTA Stock Forecast 2026-2027
$13.74
Current Price
$384.71M
Market Cap
Buy 6
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ENTA Price Targets
+103.8%
To High Target of $28.00
+45.6%
To Median Target of $20.00
+38.3%
To Low Target of $19.00
ENTA Price Momentum
+0.3%
1 Week Change
+8.5%
1 Month Change
+82.2%
1 Year Change
-12.9%
Year-to-Date Change
-19.9%
From 52W High of $17.15
+113.0%
From 52W Low of $6.45
📊 TOP ANALYST CALLS
Did ENTA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Enanta Pharmaceuticals is one of their latest high-conviction picks.
Latest ENTA Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, ENTA has a bullish consensus with a median price target of $20.00 (ranging from $19.00 to $28.00). The overall analyst rating is Strong Buy (9.7/10). Currently trading at $13.74, the median forecast implies a 45.6% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ENTA Analyst Ratings
6
Buy
0
Hold
0
Sell
ENTA Price Target Range
Low
$19.00
Average
$20.00
High
$28.00
Current: $13.74
Latest ENTA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ENTA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 23, 2026 | HC Wainwright & Co. | Brandon Folkes | Buy | Reiterates | $20.00 |
| Feb 10, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 9, 2026 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 14, 2025 | JP Morgan | Overweight | Initiates | $N/A | |
| Oct 1, 2025 | Jefferies | Buy | Upgrade | $N/A | |
| Sep 30, 2025 | WestPark Capital | Buy | Maintains | $N/A | |
| Sep 15, 2025 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Sep 2, 2025 | WestPark Capital | Buy | Initiates | $N/A | |
| Aug 12, 2025 | JMP Securities | Market Outperform | Maintains | $N/A | |
| Jul 28, 2025 | HC Wainwright & Co. | Brandon Folkes | Buy | Assumes | $20.00 |
| Jun 3, 2025 | JMP Securities | Market Outperform | Maintains | $N/A | |
| May 14, 2025 | JMP Securities | Market Outperform | Maintains | $N/A | |
| Feb 11, 2025 | JMP Securities | Market Outperform | Reiterates | $N/A | |
| Feb 11, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 24, 2024 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Nov 26, 2024 | Baird | Outperform | Maintains | $N/A | |
| Nov 26, 2024 | JMP Securities | Market Outperform | Reiterates | $N/A | |
| Oct 10, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Oct 9, 2024 | JMP Securities | Market Outperform | Reiterates | $N/A | |
| Sep 27, 2024 | JMP Securities | Market Outperform | Reiterates | $N/A |
Enanta Pharmaceuticals Inc. (ENTA) Competitors
The following stocks are similar to Enanta Pharmaceuticals based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ENTA
Enanta Pharmaceuticals
mkt cap
398.37M
Enanta Pharmaceuticals Inc. (ENTA) Financial Data
Enanta Pharmaceuticals Inc. has a market capitalization of $384.71M with a P/E ratio of -3.4x. The company generates $69.21M in trailing twelve-month revenue with a -89.6% profit margin.
Revenue growth is +15.0% quarter-over-quarter, while maintaining an operating margin of -69.1% and return on equity of -59.0%.
Valuation Metrics
Market Cap
$384.71M
Enterprise Value
$419.47M
P/E Ratio
-3.4x
PEG Ratio
0.1x
Price/Sales
5.5x
Growth & Margins
Revenue Growth (YoY)
+15.0%
Gross Margin
N/A
Operating Margin
-69.1%
Net Margin
-89.6%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+41.0%
Current Ratio
3.8x
Debt/Equity
160.1x
ROE
-59.0%
ROA
-11.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Enanta Pharmaceuticals Inc. (ENTA) Business Model
About Enanta Pharmaceuticals Inc.
What They Do
Biotechnology company focusing on small molecule drugs.
Business Model
Enanta Pharmaceuticals generates revenue through the discovery and development of innovative small molecule drugs, primarily targeting viral infections and liver diseases. The company collaborates with major pharmaceutical firms to commercialize its treatments, notably in the hepatitis C market, allowing it to benefit from licensing agreements and royalties.
Additional Information
Headquartered in Watertown, Massachusetts, Enanta operates in a competitive biotech landscape, utilizing its expertise in medicinal chemistry to develop therapies for significant health issues. The company's strong pipeline and commitment to advancing antiviral therapies position it as a key player in the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
120
CEO
Dr. Jay R. Luly Ph.D.
Country
United States
IPO Year
2013
Website
www.enanta.comEnanta Pharmaceuticals Inc. (ENTA) Latest News & Analysis
Latest News
Quick Summary
Enanta Pharmaceuticals (ENTA) experienced significant trading volume recently, but recent earnings estimate revisions may hinder its upward momentum.
Why It Matters
Higher trading volume indicates increased interest in Enanta Pharmaceuticals, but negative earnings estimate revisions could signal potential declines, impacting investor sentiment and decisions.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Enanta Pharmaceuticals announced that the European Commission has approved MAVIRET® for treating acute HCV infection in patients aged 3 and older, enhancing its market position.
Why It Matters
Enanta Pharmaceuticals' approval of MAVIRET® enhances its product portfolio, potentially increasing revenue and market share in the antiviral sector, positively influencing stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Enanta Pharmaceuticals (NASDAQ: ENTA) is advancing zelicapavir into a Phase 2b/3 trial for RSV after a successful FDA meeting, targeting adults at high risk of severe outcomes.
Why It Matters
Enanta's advancement of zelicapavir into a registrational trial signals strong FDA support, potentially leading to market approval and revenue growth, influencing investor sentiment positively.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Enanta Pharmaceuticals (NASDAQ: ENTA) executives will speak at the Jefferies Global Healthcare Conference on June 4, 2026, at 11:40 a.m. ET in New York.
Why It Matters
Enanta Pharmaceuticals' participation in a major healthcare conference may indicate upcoming developments or insights into their drug pipeline, potentially influencing stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026
2 months ago
Quick Summary
Enanta Pharmaceuticals (NASDAQ: ENTA) reported Q2 fiscal results for 2026, advancing its immunology portfolio focused on selective inhibitors for type 2 diseases.
Why It Matters
Enanta Pharmaceuticals' financial results and progress in immunology highlight its potential for growth in the biotech sector, impacting stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Enanta Pharmaceuticals (ENTA) reported a quarterly loss of $0.45 per share, slightly better than the expected loss of $0.46, compared to a loss of $1.06 per share a year prior.
Why It Matters
Enanta's smaller quarterly loss indicates improved financial performance, potentially boosting investor confidence and suggesting progress in their business strategy.
Source: Zacks Investment Research
Market Sentiment:
Negative
Frequently Asked Questions About ENTA Stock
What is Enanta Pharmaceuticals Inc.'s (ENTA) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Enanta Pharmaceuticals Inc. (ENTA) has a median price target of $20.00. The highest price target is $28.00 and the lowest is $19.00.
Is ENTA stock a good investment in 2027?
According to current analyst ratings, ENTA has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $13.74. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ENTA stock?
Wall Street analysts predict ENTA stock could reach $20.00 in the next 12 months. This represents a 45.6% increase from the current price of $13.74. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Enanta Pharmaceuticals Inc.'s business model?
Enanta Pharmaceuticals generates revenue through the discovery and development of innovative small molecule drugs, primarily targeting viral infections and liver diseases. The company collaborates with major pharmaceutical firms to commercialize its treatments, notably in the hepatitis C market, allowing it to benefit from licensing agreements and royalties.
What is the highest forecasted price for ENTA Enanta Pharmaceuticals Inc.?
The highest price target for ENTA is $28.00 from at , which represents a 103.8% increase from the current price of $13.74.
What is the lowest forecasted price for ENTA Enanta Pharmaceuticals Inc.?
The lowest price target for ENTA is $19.00 from at , which represents a 38.3% increase from the current price of $13.74.
What is the overall ENTA consensus from analysts for Enanta Pharmaceuticals Inc.?
The overall analyst consensus for ENTA is bullish. Out of 2 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $20.00.
How accurate are ENTA stock price projections?
Stock price projections, including those for Enanta Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 18, 2026 2:22 AM UTC